<DOC>
	<DOCNO>NCT02137083</DOCNO>
	<brief_summary>Comparing Docetaxel Plus Fulvestrant With Docetaxel Patients With Metastatic Breast Cancer</brief_summary>
	<brief_title>A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel Metastatic Breast Cancer</brief_title>
	<detailed_description>Comparing Docetaxel Plus Fulvestrant With Docetaxel Postmenopausal , Hormone-receptor Positive HER2-negative Metastatic Breast Cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal female 18 70 year old ECOG performance status ≤ 1 Life expectancy 3 month Histologically confirm metastatic breast cancer ER &amp; PR pqositive , HER2negative Disease progression adjuvant firstline endocrine therapy , endocrine naive unsuitable endocrine therapy alone No pretreated chemotherapy metastatic disease Have least one target lesion accord RECIST 1.1 No therapy ( chemotherapy , endocrine therapy , target therapy operation ) within 4 week enrollment Hemoglobin ≥ 90 g/L , Absolute Neutrophil Count ≥ 1.5×10^9/L , Platelet Count ≥ 75×10^9/L , Serum Bilirubin ≤ 1.5×ULN , ALT AST ≤ 1.5×ULN , Serum Creatinine ≤ 1×ULN , Endogenous Creatinine Clearance＞50ml/min Pregnant lactate woman Evidence CNS metastasis Seriously uncontrolled infection History another malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pretreated Fulvestrant Pretreated two line endocrine therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Endocrine therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Fulvestrant</keyword>
</DOC>